Skip to main content
Equibles
PHIO logo

PHIO · Phio Pharmaceuticals Corp.

Track PHIO — free

Use PHIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.13 +0.01 (+0.89%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 6, 2026
Market Cap
$13.10M
Shares
11.62M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.13 Open$1.12 Day$1.11–1.15 52W close$0.86–2.48 Avg vol 30d179K Short int320K · 2.8% float · 2.6d Short vol30% Last earningsMar 18, 2026 DataJul 2024–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Jul 5, 2024; bars on opposite sides are not compared.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −0%
below
Price vs 50-day avg +7%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 17%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +10%
trailing
6-month return −7%
trailing
YTD return +8%
this year
Relative strength −20%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$37.6K over 90 days · 0% sells
Short interest Rising
2.75% of float · ▲ +11.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 3-yr high, broad support
Squeeze score 70
high risk · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
EPS growth +81%
Y/Y
Free cash flow $-8.0M
Quant / Vol
risk profile
Very High
Volatility 82%
annualized · 1-yr
Max drawdown −65%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 5 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−0% Neutral
Price vs 50-day avg
+7% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
17% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +4 funds added
Insider flow Accumulating
Net +$37.6K over 90 days · 0% sells
Short interest Rising
2.75% of float · ▲ +11.3% MoM · 2.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
24 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 17% Range high $2
vs 200-day avg 0% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PHIO
Phio Pharmaceuticals Corp.
this stock
$13.10M +7.6% -100.0% — 2.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
24
% held
5.6%
Net QoQ
-21.4K sh
Top holder
JANE STREET GROUP, LLC
Held Float
View
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Rising
Shares short
319.7K
Days to cover
2.6d
Change
+32.4K sh
View
Short Volume
Short vol %
30%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
11.4K
Value
$12.9K
As of
Jul 22, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$37.6K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-8.7M
EPS diluted
$-9.08
View
Filings
SEC Filings
Latest
DEF 14A
Filed
Aug 14, 2026
This year
15
View
Exempt Offerings
Offering
$25.9M
Filed
Nov 12, 2025
View
Earnings & Events
Earnings Calls
Last call
Apr 14, 2026
View

Performance

Raw-price comparisons begin at the captured split on Jul 5, 2024; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
PHIO -4.2% +10.2% -6.6% +10.2% +7.6%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY -4.7% +7.3% -20.0% +7.3% -5.2%
Key facts CIK 1533040 CUSIP 71880W501 13F (30d) 20 filings 20 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)